#USA #Class Action #Philadelphia #Berger Montague #Rocket Pharmaceuticals

Urgent Reminder for Rocket Pharmaceuticals Investors

In a significant legal development, the law firm Berger Montague PC, based in Philadelphia, has reminded investors of Rocket Pharmaceuticals (NASDAQ: RCKT) about an important deadline regarding a class action lawsuit. This class action stems from allegations that the company may have concealed crucial safety risks associated with its RP-A501 trial, which has led to major financial losses for investors.

Background of the Case

Rocket Pharmaceuticals is well-known for its innovative approach in the field of genetic medicine, with its headquarters located in Cranbury, New Jersey. Recent claims indicate that the company introduced a new immunomodulatory agent into its RP-A501 protocol without proper disclosure to shareholders. This lack of transparency became critically apparent when a patient suffered a fatal adverse event during the clinical trial, a situation that was not communicated to investors in a timely manner. Shortly after this incident, the company announced a clinical hold imposed by the FDA, which caused Rocket’s stock price to plunge almost 37% within just two days of trading.

According to the details submitted in the complaint, investors who purchased securities of Rocket Pharmaceuticals during the Class Period, from September 17, 2024, to May 26, 2025, may have the right to join this class action lawsuit. The law firm emphasizes the urgency for these investors to take action, as the deadline to file for lead plaintiff status is set for August 11, 2025.

How Investors Can Respond

For those affected, it is crucial to be aware of your rights and the possible implications of this class action. Berger Montague provides resources for individuals seeking to understand their legal options, and potential participants are strongly encouraged to reach out for more information regarding joining the class action. Interested parties can inquire about their rights by contacting the firm’s representatives directly.

Contact Information

For additional information or to discuss rights involving this class action litigation, investors can reach out to:

• - Andrew Abramowitz, Senior Counsel

Berger Montague
Phone: (215) 875-3015
Email: [email protected]

• - Caitlin Adorni

Berger Montague
Phone: (267) 764-4865
Email: [email protected]

About Berger Montague

Founded in 1970, Berger Montague is well-established in the realm of securities class action litigation, focusing on protecting the rights of investors. With a broad network that includes offices across several major U.S. cities and Toronto, Canada, the firm has garnered a reputation for effectively advocating on behalf of institutional and individual investors alike. Their pioneering efforts have made them a leading force in the legal landscape, especially in matters relating to federal securities laws.

As the August deadline approaches, it is of utmost importance for affected shareholders to act promptly. Failure to join the class action before the cut-off date may result in losing the potential opportunity for recovering damages. The ongoing investigations and developments surrounding Rocket Pharmaceuticals serve as a crucial reminder for investors to remain vigilant and proactive regarding their investment rights and protections.

In conclusion, Berger Montague's notification not only seeks to inform those who have invested in Rocket Pharmaceuticals about their legal options but also underscores the critical nature of transparency and communication in the pharmaceutical industry. As further details unfold, the legal proceedings will likely continue to draw attention in the investment community.